Case Study

Reaching 108% of Goal Across Seven Phase 3 Norovirus Vaccine Sites

Seven Tekton sites across four states supported a global Phase 3 norovirus vaccine trial involving generally healthy adults. A centralized model aligned startup, regulatory, contracting, budgeting, and recruitment activity across the sites, supporting rapid first participant visits and above-goal enrollment.

  • 108% of the total enrollment goal met
  • 1 day on average from activation to first participant visit across seven sites

Talk to Tekton

senior-patients-celebrating

About This Study

CLIENT
Leading global vaccine developer
TRIAL
Global Phase 3 norovirus vaccine trial
PARTICIPANT POPULATION
Generally healthy adults
TEKTON COVERAGE
Seven sites

Partner With Tekton

Join leading Sponsors and CROs that trust Tekton's sites to support their most important clinical trials.

Complete the form on this page or email to discuss your protocol, target population, timelines, and site needs.

Submit Your Information